Global Vaccine Market Outlook 2020

Description: The pharmaceutical segment has faced diminishing prospects because of declining research and development productivity, stringent regulatory activities and generic competition for off patent products. On the contrary, vaccine segment has developed as highly profitable because of advancements in genomics and manufacturing technologies as well as increasing demand from emerging economies.

Meanwhile, continuous efforts have been put in by the biopharmaceutical companies to create tremendous opportunities for leading players to tap this market. Besides, vaccines have high entry barrier for generic players and potential to generate blockbuster sales, which thereby allure the market players.

The report, “Global Vaccine Market Outlook 2020” provides an extensive research and in-depth analysis of the current status and future outlook of the global vaccine market. The market, which stood at US$ 30.5 Billion in 2013, is expected to grow at a CAGR of around 12% during 2013-2020.

In our report, we have segmented the global vaccine market based on 16 therapeutic categories, and market for each has been forecasted. For each therapeutic segment, marketed product portfolio, pipeline products along with recent developments have been analyzed. Followed by this, important geographies have been highlighted along with their current and future markets outlook till 2020. The report also covers advanced stage pipeline analysis of key players, which list down the vaccines already in Phase III trials. Through this, our analysts have conducted a thorough opportunity assessment in various therapeutic categories and regions to clearly highlight avenues which offer maximum opportunities for growth.

In the end, various key players have been enlisted. Our team has analyzed each company's strengths and weaknesses along with its vaccine portfolio and pipeline that will help the reader to better position his company vis-a-vis competition.

Contents:
1. Analyst View
2. Research Methodology
3. Global Vaccine Market Outlook to 2020
4. Major Vaccines: Current and Future Market Analysis
   4.1 Pneumococcal
   4.2 Influenza
   4.3 Cancer
   4.4 Polio
   4.5 Varicella
   4.6 Rotavirus
   4.7 Meningococcal
   4.8 DTP
   4.9 Hepatitis
   4.10 Measles, Mumps, and Rubella (MMR)
   4.11 Japanese Encephalitis
   4.12 Tuberculosis
   4.13 Malaria
   4.14 Rabies
   4.15 Typhoid
   4.16 HIV
5. Key Geographical Markets
   5.1 US
   5.2 Europe
   5.3 Japan
   5.4 China
6. Pipeline Analysis

7. Competitive Landscape
   7.1 GSK
     7.1.1 Business Overview
     7.1.2 Vaccine Portfolio & Pipeline
     7.1.3 Strengths and Weaknesses
   7.2 Sanofi-Pasteur
     7.2.1 Business Overview
     7.2.2 Vaccine Portfolio & Pipeline
     7.2.3 Strengths and Weaknesses
   7.3 Pfizer
     7.3.1 Business Overview
     7.3.2 Vaccine Portfolio & Pipeline
     7.3.3 Strengths and Weaknesses
   7.4 Merck
     7.4.1 Business Overview
     7.4.2 Vaccine Portfolio & Pipeline
     7.4.3 Strengths and Weaknesses
   7.5 Novartis
     7.5.1 Business Overview
     7.5.2 Vaccine Portfolio & Pipeline
     7.5.3 Strengths and Weaknesses
   7.6 Emergent Biosolutions
     7.6.1 Business Overview
     7.6.2 Vaccine Portfolio & Pipeline
     7.6.3 Strengths and Weaknesses
   7.7 AstraZeneca Plc.
     7.7.1 Business Overview
     7.7.2 Vaccine Portfolio & Pipeline
     7.7.3 Strengths and Weaknesses
   7.8 Baxter International Inc.
     7.8.1 Business Overview
     7.8.2 Vaccine Portfolio & Pipeline
     7.8.3 Strengths and Weaknesses
   7.9 BioCSL (CSL Biotherapies)
     7.9.1 Business Overview
     7.9.2 Vaccine Portfolio & Pipeline
     7.9.3 Strengths and Weaknesses
   7.10 Dendreon Corporation
     7.10.1 Business Overview
     7.10.2 Vaccine Portfolio & Pipeline
     7.10.3 Strengths and Weaknesses
   7.11 Takeda Pharmaceutical Company Limited
     7.11.1 Business Overview
     7.11.2 Vaccine Portfolio & Pipeline
     7.11.3 Strengths and Weaknesses
   7.12 Crucell
     7.12.1 Business Overview
     7.12.2 Vaccine Portfolio & Pipeline
     7.12.3 Strengths and Weaknesses

List of Tables
Table 4-1: Pneumococcal Vaccine Market - Key Players and Vaccines
Table 4-2: Key Pneumococcal Vaccines in Pipeline
Table 4-3: Influenza Vaccine Market - Key Players and Vaccines
Table 4-4: Key Influenza Vaccines in Pipeline
Table 4-5: Global - Cancer Statistics in More Developed and Less Developed Regions (2008)
Table 4-6: Cancer Vaccine Market - Key Players and Vaccines
Table 4-7: Key Cancer Vaccines in Pipeline
Table 4-24: Key Tuberculosis Vaccines in Pipeline
Table 4-25: Key Malaria Vaccines in Pipeline
Table 4-26: Rabies Vaccine Market - Key Players and Vaccines
Table 4-27: Key Rabies Vaccines in Pipeline
Table 4-28: Typhoid Vaccine Market - Key Players and Vaccines
Table 4-29: Key Typhoid Vaccines in Pipeline
Table 4-30: Global - Number of HIV/AIDS Patients by Region (2009)
Table 4-31: Key HIV Vaccines in Pipeline
Table 5-1: China - Vaccine Classification
Table 6-1: Vaccine Pipeline Analysis
Table 7-1: GSK - Vaccines Portfolio
Table 7-2: GSK - Vaccines in Pipeline
Table 7-3: GSK - Strengths and Weaknesses
Table 7-4: Sanofi-Pasteur - Vaccines Portfolio
Table 7-5: Sanofi-Pasteur - Vaccines in Pipeline
Table 7-6: Sanofi-Pasteur - Strengths and Weaknesses
Table 7-7: Pfizer - Vaccines Portfolio
Table 7-8: Pfizer - Vaccines in Pipeline
Table 7-9: Pfizer - Strengths and Weaknesses
Table 7-10: Merck - Vaccines Portfolio
Table 7-11: Merck - Vaccines in Pipeline
Table 7-12: Merck - Strengths and Weaknesses
Table 7-13: Novartis - Vaccines Portfolio
Table 7-14: Novartis - Vaccines in Pipeline
Table 7-15: Novartis - Strengths and Weaknesses
Table 7-16: Emergent Biosolutions - Vaccines Portfolio
Table 7-17: Emergent Biosolutions - Vaccines in Pipeline
Table 7-18: Emergent Biosolutions - Strengths and Weaknesses
Table 7-19: AstraZeneca - Vaccines Portfolio
Table 7-20: AstraZeneca - Vaccines in Pipeline
Table 7-21: AstraZeneca - Strengths and Weaknesses
Table 7-22: Baxter International - Vaccines Portfolio
Table 7-23: Baxter International - Vaccines in Pipeline
Table 7-24: Baxter International - Strengths and Weaknesses
Table 7-25: BioCSL - Vaccines Portfolio
Table 7-26: BioCSL - Strengths and Weaknesses
Table 7-27: Dendreon Corporation - Vaccines Portfolio
Table 7-28: Dendreon Corporation - Vaccines in Pipeline
Table 7-29: Dendreon Corporation - Strengths and Weaknesses
Table 7-30: Takeda Pharmaceutical - Vaccines Portfolio
Table 7-31: Takeda Pharmaceutical - Vaccines in Pipeline
Table 7-32: Takeda Pharmaceutical - Strengths and Weaknesses
Table 7-33: Crucell - Vaccines Portfolio
Table 7-34: Crucell - Vaccines in Pipeline
Table 7-35: Crucell - Strengths and Weaknesses

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/2848277/](http://www.researchandmarkets.com/reports/2848277/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Vaccine Market Outlook 2020
Web Address: http://www.researchandmarkets.com/reports/2848277/
Office Code: SC6I5RO7

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>BOX</td>
<td>USD 1500</td>
</tr>
<tr>
<td>CD-ROM</td>
<td>BOX</td>
<td>USD 1700 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>Hard Copy</td>
<td>BOX</td>
<td>USD 1700 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>BOX</td>
<td>USD 2200</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: ___________________________ Last Name: ___________________________
First Name: _______________________
Email Address: * ___________________
Job Title: _________________________
Organisation: _______________________
Address: ___________________________
City: ______________________________
Postal / Zip Code: ___________________
Country: ___________________________
Phone Number: _______________________
Fax Number: _________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:
Please transfer funds to:

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Account number</td>
<td>833 130 83</td>
</tr>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street,</td>
</tr>
<tr>
<td></td>
<td>Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: __________________________________________________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World